Nothing Special   »   [go: up one dir, main page]

Saito et al., 2023 - Google Patents

Vaccine candidates against arenavirus infections

Saito et al., 2023

View HTML
Document ID
1633570970987738991
Author
Saito T
Reyna R
Taniguchi S
Littlefield K
Paessler S
Maruyama J
Publication year
Publication venue
Vaccines

External Links

Snippet

The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA

Similar Documents

Publication Publication Date Title
Lazarevic et al. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far?
Faburay et al. Current status of Rift Valley fever vaccine development
Chakraborty et al. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic
Al-Kassmy et al. Vaccine candidates against coronavirus infections. Where does COVID-19 stand?
Jain et al. COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response
Zhong et al. Immunogenicity and protection efficacy of a naked self-replicating mRNA-based Zika virus vaccine
Pascual-Iglesias et al. An overview of vaccines against SARS-CoV-2 in the COVID-19 pandemic era
Lopez et al. Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in cross-protection
Lukashevich Advanced vaccine candidates for Lassa fever
Evans et al. Throw out the map: neuropathogenesis of the globally expanding California serogroup of orthobunyaviruses
Salvato et al. A single dose of modified vaccinia Ankara expressing Lassa virus-like particles protects mice from lethal intra-cerebral virus challenge
Makhluf et al. Development of Zika virus vaccines
Utrilla-Trigo et al. Heterologous combination of chAdOx1 and MVA vectors expressing protein NS1 as vaccination strategy to induce durable and cross-protective CD8+ T cell immunity to bluetongue virus
Muller et al. Efficient delivery of dengue virus subunit vaccines to the skin by microprojection arrays
Zhou et al. Immune imprinting and implications for COVID-19
Zapata et al. Improving the breadth of the host’s immune response to Lassa virus
Saito et al. Vaccine candidates against arenavirus infections
Mantlo et al. Differential immune responses to hemorrhagic fever-causing arenaviruses
Johnson et al. Attenuated replication of lassa virus vaccine candidate ML29 in STAT-1-/-mice
Murphy et al. Understanding immune responses to Lassa virus infection and to its candidate vaccines
Johnson et al. Lassa virus vaccine candidate ML29 generates truncated viral RNAs which contribute to interfering activity and attenuation
Schmidt et al. A bivalent trans-amplifying RNA vaccine candidate induces potent chikungunya and ross river virus specific immune responses
Alharbi et al. Immunogenicity of high-dose MVA-based MERS vaccine candidate in mice and camels
López-Camacho et al. Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
Bhatia et al. Ebola virus glycoprotein domains associated with protective efficacy